Eosinophilic granulomatosis with polyangiitis: An overview

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Gioffredi, Andrea ^a   Maritati, Federica ^a   Oliva, Elena ^a   Buzio, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

ANCA associated vasculitis; Eosinophilic granulomatosis with polyangiitis; Eosinophils; Vascular diseases; Vasculitis

Indexed keywords

AZATHIOPRINE; CHEMOKINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; IMMUNOGLOBULIN G4; INTERLEUKIN 10; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; METHOTREXATE; OMALIZUMAB; PREDNISONE; RITUXIMAB;

ALLERGIC RHINITIS; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; EOSINOPHIL; EOSINOPHILIC GRANULOMA; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOREGULATION; PATHOGENESIS; POLYANGIITIS; REVIEW; SINUSITIS; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 84919348111     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00549     Document Type: Review

References (74)

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum (2013) 65(1):1-11. doi: 10.1002/art.37715
2. Vaglio A, Moosig F, Zwerina J. Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol (2012) 24(1):24-30. doi:10.1097/BOR.0b013e32834d85ce
3. Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun (2014) 48-49:99-103. doi:10.1016/j.jaut.2014.01.018
4. Alberici F, Martorana D, Bonatti F, Gioffredi A, Lyons PA, Vaglio A. Genetics of ANCA-associated vasculitides: HLA and beyond. Clin Exp Rheumatol (2014) 32(3 Suppl 82):90-7.
5. Wieczorek S, Hellmich B, Gross WL, Epplen JT. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum (2008) 58(1):329-30. doi:10.1002/art.23209
6. Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum (2007) 56(9):3159-66. doi:10.1002/art.22834
7. Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum (2008) 58(6):1839-48. doi:10.1002/art.23496
8. Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax (2010) 65(2):132-8. doi:10.1136/thx.2009.120972
9. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest (2009) 136(2):507-18. doi:10.1378/chest.08-2990
10. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol (2007) 144(2):155-8. doi:10.1159/000103228
11. Puechal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med (2008) 19(5):364-6. doi:10.1016/j.ejim.2007.09.001
12. Gomez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev (2013) 12(12):1129-35. doi:10.1016/j.autrev.2013.06.016
13. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature (1986) 321(6070):613-6. doi:10.1038/321613a0
14. Shah AM, Brutsaert DL, Meulemans AL, Andries LJ, Capron M. Eosinophils from hypereosinophilic patients damage endocardium of isolated feline heart muscle preparations. Circulation (1990) 81(3):1081-8. doi:10.1161/01.CIR.81.3.1081
15. Maino A, Rossio R, Cugno M, Marzano AV, Tedeschi A. Hypereosinophilic syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. Curr Vasc Pharmacol (2012) 10(5):670-5. doi:10.2174/157016112801784594
16. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest (1993) 91(4):1721-30. doi:10.1172/JCI116382
17. Terrier B, Bièche I, Maisonobe T, Laurendeau I, Rosenzwajg M, Kahn JE, et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood (2010) 116(22):4523-31. doi:10.1182/blood-2010-02-267542
18. Schmitt WH, Csernok E, Kobayashi S, Klinkenborg A, Reinhold-Keller E, Gross WL. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum (1998) 41(3):445-52. doi:10.1002/1529-0131(199803)41:3<445::AID-ART10>3.3.CO;2-V
19. Guida G, Vallario A, Stella S, Boita M, Circosta P, Mariani S, et al. Clonal CD8+ TCR-Vbeta expanded populations with effector memory phenotype in Churg Strauss syndrome. Clin Immunol (2008) 128(1):94-102. doi:10.1016/j.clim.2008.03.505
20. Boita M, Guida G, Circosta P, Elia AR, Stella S, Heffler E, et al. The molecular and functional characterization of clonally expanded CD8+ TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA). Clin Immunol (2014) 152(1-2):152-63. doi:10.1016/j.clim.2014.03.001
21. Lepse N, Abdulahad WH, Kallenberg CG, Heeringa P. Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev (2011) 11(2):77-83. doi:10.1016/j.autrev.2011.08.002
22. Free ME, Bunch DO, McGregor JA, Jones BE, Berg EA, Hogan SL, et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum (2013) 65(7):1922-33. doi:10.1002/art.37959
23. Jennette JC, Xiao H, Falk R, Gasim AM. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib Nephrol (2011) 169:211-20. doi:10.1159/000314776
24. Vaglio A, Strehl JD, Manger B, Maritati F, Alberici F, Beyer C, et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis (2012) 71(3):390-3. doi:10.1136/ard.2011.155382
25. Zwerina J, Bach C, Martorana D, Jatzwauk M, Hegasy G, Moosig F, et al. Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 50(10):1823-7. doi:10.1093/rheumatology/keq445
26. Polzer K, Karonitsch T, Neumann T, Eger G, Haberler C, Soleiman A, et al. Eotaxin-3 is involved in Churg-Strauss syndrome - a serum marker closely correlating with disease activity. Rheumatology (Oxford) (2008) 47(6):804-8. doi:10.1093/rheumatology/ken033
27. Jakiela B, Sanak M, Szczeklik W, Sokolowska B, Plutecka H, Mastalerz L, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol (2011) 29(1 Suppl 64):S23-34.
28. Kiene M, Csernok E, Müller A, Metzler C, Trabandt A, Gross WL. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum (2001) 44(2):469-73. doi:10.1002/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0
29. Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy (2013) 68(3):261-73. doi:10.1111/all.12088
30. Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum (2013) 65(1):270-81. doi:10.1002/art.37721
31. Sablé-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med (2005) 143(9):632-8. doi:10.7326/0003-4819-143-9-200511010-00006
32. Bacciu A, Bacciu S, Mercante G, Ingegnoli F, Grasselli C, Vaglio A, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol (2006) 126(5):503-9. doi:10.1080/00016480500437435
33. Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis (2006) 47(5):770-9. doi:10.1053/j.ajkd.2006.01.026
34. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum (2005) 52(9):2926-35. doi:10.1002/art.21250
35. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol (2007) 19(1):25-32. doi:10.1097/BOR.0b013e3280119854
36. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) (1999) 78(1):26-37. doi:10.1097/00005792-199901000-00003
37. Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med (1994) 150(5 Pt 1):1423-38. doi:10.1164/ajrccm.150.5.7952571
38. Neumann T, Manger B, Schmid M, Kroegel C, Hansch A, Kaiser WA, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 88(4):236-43. doi:10.1097/MD.0b013e3181af35a5
39. Schwartz RA, Churg J. Churg-Strauss syndrome. Br J Dermatol (1992) 127(3):199-204. doi:10.1111/j.1365-2133.1992.tb00114.x
40. Bosco L, Peroni A, Schena D, Colato C, Girolomoni G. Cutaneous manifestations of Churg-Strauss syndrome: report of two cases and review of the literature. Clin Rheumatol (2011) 30(4):573-80. doi:10.1007/s10067-010-1593-1
41. Cattaneo L, Chierici E, Pavone L, Grasselli C, Manganelli P, Buzio C, et al. Peripheral neuropathy in Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry (2007) 78(10):1119-23. doi:10.1136/jnnp.2006.111013
42. Vaglio A, Corradi D, Ronda N, Garini G, Buzio C. Large bowel obstruction heralding Churg-Strauss syndrome. Am J Gastroenterol (2004) 99(3):562-3. doi:10.1111/j.1572-0241.2004.04105.x
43. Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest (1995) 108(2):320-3. doi:10.1378/chest.108.2.320
44. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) (1984) 63(2):65-81. doi:10.1097/00005792-198403000-00001
45. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med (2003) 115(4):284-90. doi:10.1016/S0002-9343(03)00359-0
46. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum (1990) 33(8):1094-100. doi:10.1002/art.1780330806
47. Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum (1990) 33(8):1074-87. doi:10.1002/art.1780330804
48. Vaglio A, Casazza I, Grasselli C, Corradi D, Sinico RA, Buzio C. Churg-Strauss syndrome. Kidney Int (2009) 76(9):1006-11. doi:10.1038/ki.2009.210
49. Corradi D, Vaglio A, Maestri R, Legname V, Leonardi G, Bartoloni G, et al. Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. Hum Pathol (2004) 35(9):1160-3. doi:10.1016/j.humpath.2004.05.008
50. Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 126(1):45-9. doi:10.1016/j.jaci.2010.03.042
51. Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol (2009) 23(3):355-66. doi:10.1016/j.berh.2009.02.004
52. Wechsler ME. Pulmonary eosinophilic syndromes. Immunol Allergy Clin North Am (2007) 27(3):477-92. doi:10.1016/j.iac.2007.07.005
53. Vaglio A, Zwerina J. IgG4-related disease. N Engl J Med (2012) 366(17):1643-47. doi:10.1056/NEJMc1202768$SA5
54. Mahr A, Moosig F, Neumann T, Szczeklik W, Taillé C, Vaglio A, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol (2014) 26(1):16-23. doi:10.1097/BOR.0000000000000015
55. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) (2011) 90(1):19-27. doi:10.1097/MD.0b013e318205a4c6
56. Jayne D. New-generation therapy for ANCA-associated vasculitis. Clin Exp Nephrol (2013) 17(5):694-6. doi:10.1007/s10157-013-0855-z
57. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM (1994) 87(11):671-8.
58. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 116(6):488-98. doi:10.7326/0003-4819-116-6-488
59. Cohen P, Pagnoux C, Mahr A, Arène JP, Mouthon L, Le Guern V, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum (2007) 57(4):686-93. doi:10.1002/art.22679
60. de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol (2007) 4(12):686-94. doi:10.1038/ncpgasthep1000
61. Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) (2008) 47(7):1104-5. doi:10.1093/rheumatology/ken175
62. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2009) 60(7):2156-68. doi:10.1002/art.24637
63. Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant (2011) 26(9):2865-71. doi:10.1093/ndt/gfq852
64. Saech J, Owczarczyk K, Roesgen S, Hallek M, Rubbert A. Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis (2010) 69(6):1254-5. doi:10.1136/ard.2009.109850
65. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis (2006) 65(8):1116-7. doi:10.1136/ard.2005.047308
66. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis (2006) 65(4):557-9. doi:10.1136/ard.2005.042937
67. Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther (2013) 15(5):R133. doi:10.1186/ar4313
68. Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol (2010) 125(1):267-70. doi:10.1016/j.jaci.2009.10.014
69. Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med (2011) 155(5):341-3. doi:10.7326/0003-4819-155-5-201109060-00026
70. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol (2010) 125(6):1336-43. doi:10.1016/j.jaci.2010.03.028
71. Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol (2008) 26(3 Suppl 49):S35-40.
72. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med (1998) 129(5):370-4. doi:10.7326/0003-4819-129-5-199809010-00004
73. Samson M, Puéchal X, Devilliers H, Ribi C, Cohen P, Stern M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun (2013) 43:60-9. doi:10.1016/j.jaut.2013.03.003
74. Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis (2013) 72(6):1011-7. doi:10.1136/annrheumdis-2012-201531